95.06 USD
+0.77
0.82%
At close Apr 28, 4:00 PM EDT
After hours
95.06
+0.00
0.00%
1 day
0.82%
5 days
3.79%
1 month
-10.00%
3 months
-24.31%
6 months
-19.09%
Year to date
-15.12%
1 year
-9.48%
5 years
7.47%
10 years
83.66%
 

About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Employees: 11,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

20% more call options, than puts

Call options by funds: $1.77M | Put options by funds: $1.48M

19% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 161

15% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 60

3.87% more ownership

Funds ownership: 87.62% [Q3] → 91.49% (+3.87%) [Q4]

0% more funds holding

Funds holding: 517 [Q3] → 518 (+1) [Q4]

4% less capital invested

Capital invested by funds: $13.8B [Q3] → $13.2B (-$544M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$102
7%
upside
Avg. target
$126
32%
upside
High target
$145
53%
upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
Baird
Catherine Ramsey
28% 1-year accuracy
5 / 18 met price target
34%upside
$127
Outperform
Maintained
21 Apr 2025
Wells Fargo
Brandon Couillard
8% 1-year accuracy
2 / 25 met price target
7%upside
$102
Equal-Weight
Maintained
17 Apr 2025
Barclays
Luke Sergott
32% 1-year accuracy
19 / 59 met price target
16%upside
$110
Overweight
Maintained
10 Apr 2025
Raymond James
Andrew Cooper
24% 1-year accuracy
4 / 17 met price target
53%upside
$145
Outperform
Reiterated
3 Feb 2025
Keybanc
Paul Knight
11% 1-year accuracy
1 / 9 met price target
53%upside
$145
Overweight
Maintained
3 Feb 2025

Financial journalist opinion

Based on 17 articles about RVTY published over the past 30 days

Positive
Zacks Investment Research
16 hours ago
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Neutral
Seeking Alpha
18 hours ago
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and I will be coordinating your call today.
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
19 hours ago
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Positive
Benzinga
21 hours ago
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Positive
Zacks Investment Research
22 hours ago
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.98 per share a year ago.
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
Positive
Reuters
22 hours ago
Revvity beats quarterly estimates on steady demand for medical equipment
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for drug research.
Revvity beats quarterly estimates on steady demand for medical equipment
Neutral
Business Wire
1 day ago
Revvity Announces Financial Results for the First Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operati.
Revvity Announces Financial Results for the First Quarter of 2025
Positive
Zacks Investment Research
3 days ago
Why Revvity (RVTY) Could Beat Earnings Estimates Again
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Revvity (RVTY) Could Beat Earnings Estimates Again
Neutral
Zacks Investment Research
3 days ago
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
Neutral
Business Wire
4 days ago
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery.
Revvity Board Declares Quarterly Dividend
Charts implemented using Lightweight Charts™